Oleg I Krijanovski, M.D., Ph.D.
Investigator
Dr. Oleg I. Krijanovski is a board‑certified medical oncologist and hematologist with more than three decades of clinical, academic, and research experience spanning the United States and internationally. He currently serves as the Medical Director of the Malignant Hematology and Blood & Marrow Transplantation Program at Alta Bates Summit Medical Center in Berkeley, California. Trained in Russia, Vienna, and the University of Michigan, Dr. Krijanovski has extensive expertise in bone marrow transplantation, graft‑versus‑host disease, and hematologic malignancies. His career includes leadership roles in pediatric and adult transplant programs and principal investigator positions on numerous national and international clinical trials. A widely published researcher, he has contributed to advancements in GVHD biomarkers, transplant immunology, and conditioning regimens. Dr. Krijanovski is also an active educator, lecturer, and consultant to leading pharmaceutical organizations, recognized for his lifelong commitment to improving outcomes for patients with complex blood disorders.
Research studies
- Research study
Bone Marrow Transplant Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Clinical trials
- Clinical trial
Adjuvant Large B-Cell Lymphoma Alpha3
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Status: Open to Enrollment
- Clinical trial
Adverse Effects of Chemotherapy Shengbai Solution
A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy
Status: Open to Enrollment
- Clinical trial
Lymphoma, Large B-Cell, Diffuse Expanded Access For Subjects Receiving Lisocabtagen Maraleucel JCAR017-EAP-001
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release (JCAR017-EAP-001)
Status: Open to Enrollment
- Clinical trial
Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
Status: Open to Enrollment
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Status: Coming Soon




